U.S. Markets open in 54 mins
  • S&P Futures

    4,062.50
    +57.75 (+1.44%)
     
  • Dow Futures

    32,514.00
    +355.00 (+1.10%)
     
  • Nasdaq Futures

    12,476.00
    +231.25 (+1.89%)
     
  • Russell 2000 Futures

    1,811.10
    +28.70 (+1.61%)
     
  • Crude Oil

    113.84
    -0.36 (-0.32%)
     
  • Gold

    1,829.00
    +15.00 (+0.83%)
     
  • Silver

    21.69
    +0.14 (+0.64%)
     
  • EUR/USD

    1.0536
    +0.0098 (+0.9377%)
     
  • 10-Yr Bond

    2.9190
    +0.0420 (+1.46%)
     
  • Vix

    26.67
    -2.20 (-7.62%)
     
  • GBP/USD

    1.2482
    +0.0158 (+1.2819%)
     
  • USD/JPY

    129.4770
    +0.4240 (+0.3286%)
     
  • BTC-USD

    30,479.48
    +383.09 (+1.27%)
     
  • CMC Crypto 200

    685.81
    +443.13 (+182.60%)
     
  • FTSE 100

    7,522.23
    +57.43 (+0.77%)
     
  • Nikkei 225

    26,659.75
    +112.70 (+0.42%)
     

GoodRx Rises Despite Weak Earnings, Forecast

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Christiana Sciaudone

Investing.com -- Goodrx Holdings Inc (NASDAQ:GDRX) rose 6% despite reporting earnings and guidance that missed the mark, if by a small margin.

Earnings per share of 7 cents missed expectations by a hair while sales of $160.4 million fell just short of the $160.5 million analysts had forecast, according to data compiled by Investing.com. Revenue for the year was estimated at $740 million to $760 million, versus the consensus of $748 million, according to StreetInsider. On the slightly more positive side, sales for the second quarter are expected at $172 million to $176 million versus the forecast of $172.4 million.

Shares of GoodRx have slipped more than 40% since the company went public in September. The threat of Amazon (NASDAQ:AMZN) has since reared its giant head in the world of healthcare, sending shivers down the spines of investors who fear that GoodRx could take a major hit from the rivalry.

Analysts from RBC Capital to Barclays (LON:BARC) dropped the company's price target following the first quarter results.

On Thursday, Bloomberg, citing people familiar with the situation, reported that GoodRx bought discount drug company RxSaver from Vericast Corp., controlled by billionaire Ronald Perelman.

Corrects year-revenue estimate to reflect $748 million forecast.

Related Articles

GoodRx Rises Despite Weak Earnings, Forecast

Danone names Barry Callebaut's Saint-Affrique as new CEO

Investment firms bet on stocks hit by Archegos unwind